Renshi Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Renshi Xu has a total of 285 co-authors. Here are the top co-authors by number of shared publications:
Wenzhi Chen
Department of Neurology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang
18 shared publicationsJie Zhang
Department of Neurology, First Affiliated Hospital of Nanchang University, Nanchang, China
14 shared publicationsYu Zhu
Department of Neurology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
12 shared publications- Xiong Zhang
Department of Neurology, Maoming People’s Hospital
11 shared publications Shu Li
Department of Neurology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang
10 shared publicationsCheng Li
Department of Neurology Jiangxi Provincial People's Hospital, the First Affiliated Hospital of Nanchang Medical College, National Regional Medical Center for Nervous Disease Nanchang Jiangxi China
9 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Walter de Gruyter GmbH in Reviews in the Neurosciences
Current findings, application, and diagnosis of magnetic resonance imaging in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative disorder within the motor neuron disease (MND) spectrum, characterized by progressive degeneration of upper and lower motor neurons. The clinical phenotype ranges from pure motor syndromes to forms with cognitive and behavioral impairment, and the pathological burden extends beyond the motor system. Diagnosis remains primarily clinical, supported by electrophysiology and exclusion of mimics. Therefore, objective imaging biomarkers are urgently needed. Magnetic resonance imaging (MRI) is widely used as an auxiliary and differential diagnostic tool in ALS. T1- and T2-weighted imaging can assess cortical thickness, gray matter atrophy, and signal changes. Diffusion tensor imaging probes white matter microstructure. Magnetic resonance spectroscopy detects neurochemical alterations. Resting-state functional MRI assesses functional connectivity and network organization. Susceptibility-weighted imaging is sensitive to iron and calcium deposition. Ultra-high-field MRI provides higher resolution and improved metabolite quantification. This critical review summarizes current findings on MRI in ALS, but importantly organizes the evidence by the specific question being addressed: pathological/histological correlates, diagnostic or discriminatory performance, and clinical associations with phenotype, severity, progression, and prognosis. We also discuss major limitations, including methodological heterogeneity, limited standardization, small and clinically heterogeneous cohorts, frequent use of healthy rather than disease controls, and scarce multicenter validation. Although advanced MRI has revealed robust group-level alterations, none of these techniques has yet become established in routine clinical diagnosis of ALS. We, therefore, distinguish promising research findings from validated clinical biomarkers and outline priorities for future translation.
- 4 November 2026
- Published by Walter de Gruyter GmbH in Reviews in the Neurosciences
Open AccessCurrent findings, application, and diagnosis of magnetic resonance imaging in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative disorder within the motor neuron disease (MND) spectrum, characterized by progressive degeneration of upper and lower motor neurons. The clinical phenotype ranges from pure motor syndromes to forms with cognitive and behavioral impairment, and the pathological burden extends beyond the motor system. Diagnosis remains primarily clinical, supported by electrophysiology and exclusion of mimics. Therefore, objective imaging biomarkers are urgently needed. Magnetic resonance imaging (MRI) is widely used as an auxiliary and differential diagnostic tool in ALS. T1- and T2-weighted imaging can assess cortical thickness, gray matter atrophy, and signal changes. Diffusion tensor imaging probes white matter microstructure. Magnetic resonance spectroscopy detects neurochemical alterations. Resting-state functional MRI assesses functional connectivity and network organization. Susceptibility-weighted imaging is sensitive to iron and calcium deposition. Ultra-high-field MRI provides higher resolution and improved metabolite quantification. This critical review summarizes current findings on MRI in ALS, but importantly organizes the evidence by the specific question being addressed: pathological/histological correlates, diagnostic or discriminatory performance, and clinical associations with phenotype, severity, progression, and prognosis. We also discuss major limitations, including methodological heterogeneity, limited standardization, small and clinically heterogeneous cohorts, frequent use of healthy rather than disease controls, and scarce multicenter validation. Although advanced MRI has revealed robust group-level alterations, none of these techniques has yet become established in routine clinical diagnosis of ALS. We, therefore, distinguish promising research findings from validated clinical biomarkers and outline priorities for future translation.
- Open Access
- 29 September 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1915475
Clemastine alleviates Parkinson’s disease pathology by activating the AMPK/mTOR pathway and enhancing autophagic flux
Parkinson’s disease (PD) is a debilitating neurodegenerative disorder with no available cure, underscoring the urgent need for novel therapeutics. This study employed the comprehensive bioinformatic analyses and the experimental models to investigate the potential of clemastine (CLE) for PD treatment. Bioinformatics identified 12 distinct cell subtypes and 577 differentially expressed genes in dopaminergic neurons (DaNs), along with 167 potential PD-relevant CLE targets. A significant correlation was found between Braak stage and autophagy-related gene expression in the substantia nigra. In MPP + -induced PC12 cell model, CLE treatment increased AMPK phosphorylation and decreased mTOR phosphorylation at Ser2448, suggesting the activation of AMPK and reduced mTOR activity, which was accompanied by the reduced levels of α-synuclein (α-syn) and p62, increased lysosomal (LAMP1) and autophagosomal (LC3) markers, and enhanced cell viability. CLE increased the LC3-II/LC3-I ratio even in the presence of bafilomycin A1, indicating enhanced autophagosome synthesis. Conversely, the AMPK inhibitor dorsomorphin blocked CLE effects, restoring mTOR phosphorylation and α-syn levels. In the chronic MPTP-induced mouse model, CLE administration increased the phosphorylation of AMPK, increased the LC3-II/LC3-I ratio, and decreased mTOR phosphorylation, p62, and α-syn levels. Immunofluorescence revealed the increased DaNs (tyrosine hydroxylase-positive) and LC3 puncta, alongside reduced the phosphorylated α-syn (p-S129). These cellular and molecular improvements correlated with the alleviation of both motor (rotarod test) and non-motor (fecal pellet output) deficits. Collectively, our findings suggest that CLE alleviates PD pathology by increasing AMPK phosphorylation and decreasing mTOR phosphorylation at Ser2448, suggesting the activation of AMPK pathway and reduced mTOR activity, thereby enhancing the autophagic flux by promoting both the synthesis and degradation of autophagosomes. Subsequently it facilitates the clearance of pathological α-syn, improves the neuronal survival, and ameliorates the behavioral symptoms. We propose CLE as a promising therapeutic candidate for PD via autophagy modulation.
- 29 September 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1915475
Open AccessClemastine alleviates Parkinson’s disease pathology by activating the AMPK/mTOR pathway and enhancing autophagic flux
Parkinson’s disease (PD) is a debilitating neurodegenerative disorder with no available cure, underscoring the urgent need for novel therapeutics. This study employed the comprehensive bioinformatic analyses and the experimental models to investigate the potential of clemastine (CLE) for PD treatment. Bioinformatics identified 12 distinct cell subtypes and 577 differentially expressed genes in dopaminergic neurons (DaNs), along with 167 potential PD-relevant CLE targets. A significant correlation was found between Braak stage and autophagy-related gene expression in the substantia nigra. In MPP + -induced PC12 cell model, CLE treatment increased AMPK phosphorylation and decreased mTOR phosphorylation at Ser2448, suggesting the activation of AMPK and reduced mTOR activity, which was accompanied by the reduced levels of α-synuclein (α-syn) and p62, increased lysosomal (LAMP1) and autophagosomal (LC3) markers, and enhanced cell viability. CLE increased the LC3-II/LC3-I ratio even in the presence of bafilomycin A1, indicating enhanced autophagosome synthesis. Conversely, the AMPK inhibitor dorsomorphin blocked CLE effects, restoring mTOR phosphorylation and α-syn levels. In the chronic MPTP-induced mouse model, CLE administration increased the phosphorylation of AMPK, increased the LC3-II/LC3-I ratio, and decreased mTOR phosphorylation, p62, and α-syn levels. Immunofluorescence revealed the increased DaNs (tyrosine hydroxylase-positive) and LC3 puncta, alongside reduced the phosphorylated α-syn (p-S129). These cellular and molecular improvements correlated with the alleviation of both motor (rotarod test) and non-motor (fecal pellet output) deficits. Collectively, our findings suggest that CLE alleviates PD pathology by increasing AMPK phosphorylation and decreasing mTOR phosphorylation at Ser2448, suggesting the activation of AMPK pathway and reduced mTOR activity, thereby enhancing the autophagic flux by promoting both the synthesis and degradation of autophagosomes. Subsequently it facilitates the clearance of pathological α-syn, improves the neuronal survival, and ameliorates the behavioral symptoms. We propose CLE as a promising therapeutic candidate for PD via autophagy modulation.
- Open Access
- 1 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70653
Distinct UNC13A Haplotype Blocks Define Disease Severity and Survival in Chinese Amyotrophic Lateral Sclerosis
Background: UNC13A is a genetic modifier of amyotrophic lateral sclerosis (ALS) in European populations, but its role in Chinese patients remains incompletely characterized. We investigated the spectrum of UNC13A variation and its impact on disease risk and progression in a Chinese ALS cohort. Methods: We performed an integrated genetic analysis of 1,533 Chinese ALS patients and 1,405 controls, including rare variant burden testing, genome‐wide survival analysis, haplotype mapping, and conditional analyses. An integrated clinical‐genetic prognostic score was developed and validated. Results: Rare deleterious UNC13A variants were not associated with ALS risk. We identified two independent haplotype blocks with distinct clinical impacts. Block 1 (tagged by rs75421007) was associated with reduced baseline muscle strength ( p = 0.030), while Block 2 (tagged by rs78549703), a brain‐specific splicing QTL, was the primary driver of survival heterogeneity. The European variant rs12608932 showed a survival association in single‐marker analysis ( p = 0.024), but conditional analyses revealed its effect was not independent of Block 2. An integrated prognostic score combining clinical factors and Block 2 haplotype stratified patients into low‐, intermediate‐, and high‐risk groups (median survival: 52.6, 37.1, and 32.0 months; p < 0.001), with decision curve analysis confirming clinical utility. Conclusions: This study delineates UNC13A genetic architecture in Chinese ALS, identifying two independent haplotype blocks that differentially influence disease severity and survival. The Block 2 haplotype, which includes a brain sQTL, is a major determinant of survival heterogeneity and may inform patient stratification in future studies.
- 1 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70653
Open AccessDistinct UNC13A Haplotype Blocks Define Disease Severity and Survival in Chinese Amyotrophic Lateral Sclerosis
Background: UNC13A is a genetic modifier of amyotrophic lateral sclerosis (ALS) in European populations, but its role in Chinese patients remains incompletely characterized. We investigated the spectrum of UNC13A variation and its impact on disease risk and progression in a Chinese ALS cohort. Methods: We performed an integrated genetic analysis of 1,533 Chinese ALS patients and 1,405 controls, including rare variant burden testing, genome‐wide survival analysis, haplotype mapping, and conditional analyses. An integrated clinical‐genetic prognostic score was developed and validated. Results: Rare deleterious UNC13A variants were not associated with ALS risk. We identified two independent haplotype blocks with distinct clinical impacts. Block 1 (tagged by rs75421007) was associated with reduced baseline muscle strength ( p = 0.030), while Block 2 (tagged by rs78549703), a brain‐specific splicing QTL, was the primary driver of survival heterogeneity. The European variant rs12608932 showed a survival association in single‐marker analysis ( p = 0.024), but conditional analyses revealed its effect was not independent of Block 2. An integrated prognostic score combining clinical factors and Block 2 haplotype stratified patients into low‐, intermediate‐, and high‐risk groups (median survival: 52.6, 37.1, and 32.0 months; p < 0.001), with decision curve analysis confirming clinical utility. Conclusions: This study delineates UNC13A genetic architecture in Chinese ALS, identifying two independent haplotype blocks that differentially influence disease severity and survival. The Block 2 haplotype, which includes a brain sQTL, is a major determinant of survival heterogeneity and may inform patient stratification in future studies.
- Open Access
- 29 May 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (6) , e70946
5‐Hydroxytryptamine Distribution Alteration in Both Neuron and Synapse of Tg( SOD1 * G93A )1gur Mice: A Potential Intervention Candidate Strategy for Amyotrophic Lateral Sclerosis
Aims: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease; the precise pathogenesis of sporadic ALS (sALS) has not yet been elucidated up to now. Previous studies revealed that the abnormal alterations of some non‐motor neurons (non‐MN) were a potential pathogenesis of sALS. Therefore, this study aims to search the potential evidences of non‐MN in the pathogenesis of ALS via exploring potential relationships between 5‐hydroxytryptamine (5‐HT) neurons and the development of ALS. Methods: We employed fluorescent immunohistochemistry to investigate the altered distribution patterns of 5‐HT and tryptophan hydroxylase 2 in the spinal cord and brainstem of Tg(SOD1*G93A)1Gur (TG) and wild‐type (WT) mice. Additionally, we used western blot to analyze the expression levels of 5‐hydroxytryptamine receptor 1A (5‐HTR1A) and 5‐HTR2A. Results: Our findings revealed that 5‐HT synapses were primarily distributed in the funiculus lateralis, anterior horn, posterior horn, central lateral column, and the area around the central canal of cervical, thoracic, and lumbar segments, and raphe nucleus as well as lateral paragigantocellular nucleus, and gradually reduced following age increase in WT mice. However, 5‐HT synapses in the spinal cord and 5‐HT neurons in the brainstem gradually increased following the progression of disease and presented a significantly negative correlation between the increased distribution of 5‐HT synapses and neurons and the reduction of neural cell number (positively correlated with the increase in neural cell death) at the onset and/or progression stage of TG mice. 5‐HTR1A significantly increased, while 5‐HTR2A significantly decreased at the onset stage of TG mice. Conclusion: Our study speculated that the distribution changes of 5‐HT synapses in the spinal cord and 5‐HT neurons in the brainstem play a potential protective role in the pathogenesis of sALS through a compensatory 5‐HT increase.
- 29 May 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (6) , e70946
Open Access5‐Hydroxytryptamine Distribution Alteration in Both Neuron and Synapse of Tg( SOD1 * G93A )1gur Mice: A Potential Intervention Candidate Strategy for Amyotrophic Lateral Sclerosis
Aims: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease; the precise pathogenesis of sporadic ALS (sALS) has not yet been elucidated up to now. Previous studies revealed that the abnormal alterations of some non‐motor neurons (non‐MN) were a potential pathogenesis of sALS. Therefore, this study aims to search the potential evidences of non‐MN in the pathogenesis of ALS via exploring potential relationships between 5‐hydroxytryptamine (5‐HT) neurons and the development of ALS. Methods: We employed fluorescent immunohistochemistry to investigate the altered distribution patterns of 5‐HT and tryptophan hydroxylase 2 in the spinal cord and brainstem of Tg(SOD1*G93A)1Gur (TG) and wild‐type (WT) mice. Additionally, we used western blot to analyze the expression levels of 5‐hydroxytryptamine receptor 1A (5‐HTR1A) and 5‐HTR2A. Results: Our findings revealed that 5‐HT synapses were primarily distributed in the funiculus lateralis, anterior horn, posterior horn, central lateral column, and the area around the central canal of cervical, thoracic, and lumbar segments, and raphe nucleus as well as lateral paragigantocellular nucleus, and gradually reduced following age increase in WT mice. However, 5‐HT synapses in the spinal cord and 5‐HT neurons in the brainstem gradually increased following the progression of disease and presented a significantly negative correlation between the increased distribution of 5‐HT synapses and neurons and the reduction of neural cell number (positively correlated with the increase in neural cell death) at the onset and/or progression stage of TG mice. 5‐HTR1A significantly increased, while 5‐HTR2A significantly decreased at the onset stage of TG mice. Conclusion: Our study speculated that the distribution changes of 5‐HT synapses in the spinal cord and 5‐HT neurons in the brainstem play a potential protective role in the pathogenesis of sALS through a compensatory 5‐HT increase.
- Open Access
- 6 February 2026
- Published by Taylor & Francis in Dialogues in clinical neuroscience
- Vol. 28 (1) , 62-84
Current potential biomarkers for Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: review of literature
Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS) are several common neurodegenerative diseases (NDs). At present, is the lack of effective diagnosis, progression, prognosis and therapeutic biomarkers. it is a urgent demand to search the relevant confident biomarkers. This review systematically analysed the potential biomarkers of blood, cerebrospinal fluid, neuroimaing and emerging non-invasive indicators, and synthesises current evidences on the biomarkers of AD, PD and ALS about diagnosis, progression, prognosis and therapeutic, especially diagnosis biomarkers. In this review, we focus on discussing relevant diagnosis, progression, prognosis and therapeutic biomarkers for AD, PD and ALS in recent years, and prospecting the possible future directions of relevant biomarkers.
- 6 February 2026
- Published by Taylor & Francis in Dialogues in clinical neuroscience
- Vol. 28 (1) , 62-84
Open AccessCurrent potential biomarkers for Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: review of literature
Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS) are several common neurodegenerative diseases (NDs). At present, is the lack of effective diagnosis, progression, prognosis and therapeutic biomarkers. it is a urgent demand to search the relevant confident biomarkers. This review systematically analysed the potential biomarkers of blood, cerebrospinal fluid, neuroimaing and emerging non-invasive indicators, and synthesises current evidences on the biomarkers of AD, PD and ALS about diagnosis, progression, prognosis and therapeutic, especially diagnosis biomarkers. In this review, we focus on discussing relevant diagnosis, progression, prognosis and therapeutic biomarkers for AD, PD and ALS in recent years, and prospecting the possible future directions of relevant biomarkers.
- Open Access
- 27 January 2026
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (11) , 5181-5195
Amyotrophic lateral sclerosis: Neural repair strategies based on multi-target synchronous interventions
Amyotrophic lateral sclerosis is a progressive and fatal neurodegenerative disease that targets motor neurons in the cerebral cortex, medulla oblongata, and spinal cord. This review focuses on the current concepts in the aetiopathogenesis and diagnosis of amyotrophic lateral sclerosis, aiming to explore potential neural repair strategies (curative and/or progression-retarding therapeutics). Recent studies have highlighted that the complex pathogenesis of amyotrophic lateral sclerosis is related to its multifactorial aetiology, including proteostasis disruption, impaired RNA metabolism and DNA repair, cytoskeletal and axonal transport defects, excitotoxicity, neuroinflammation, mitochondrial dysfunction, oligodendrocyte dysfunction, nucleocytoplasmic transport deficits, lipid dyshomeostasis, and autophagy. Several approved drugs are currently used to treat patients with amyotrophic lateral sclerosis; however, their curative efficacy is limited. Thus, the search for effective therapeutic strategies for amyotrophic lateral sclerosis requires a comprehensive understanding of its pathogenesis. Current evidence indicates that a single drug cannot provide a satisfactory therapeutic effect. Additionally, multiple pathophysiological processes and related targets are involved in the pathogenesis of amyotrophic lateral sclerosis. Therefore, research on multi-target synchronous interventions may be the path forward for discovering and developing potential neural repair strategies.
- 27 January 2026
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (11) , 5181-5195
Open AccessAmyotrophic lateral sclerosis: Neural repair strategies based on multi-target synchronous interventions
Amyotrophic lateral sclerosis is a progressive and fatal neurodegenerative disease that targets motor neurons in the cerebral cortex, medulla oblongata, and spinal cord. This review focuses on the current concepts in the aetiopathogenesis and diagnosis of amyotrophic lateral sclerosis, aiming to explore potential neural repair strategies (curative and/or progression-retarding therapeutics). Recent studies have highlighted that the complex pathogenesis of amyotrophic lateral sclerosis is related to its multifactorial aetiology, including proteostasis disruption, impaired RNA metabolism and DNA repair, cytoskeletal and axonal transport defects, excitotoxicity, neuroinflammation, mitochondrial dysfunction, oligodendrocyte dysfunction, nucleocytoplasmic transport deficits, lipid dyshomeostasis, and autophagy. Several approved drugs are currently used to treat patients with amyotrophic lateral sclerosis; however, their curative efficacy is limited. Thus, the search for effective therapeutic strategies for amyotrophic lateral sclerosis requires a comprehensive understanding of its pathogenesis. Current evidence indicates that a single drug cannot provide a satisfactory therapeutic effect. Additionally, multiple pathophysiological processes and related targets are involved in the pathogenesis of amyotrophic lateral sclerosis. Therefore, research on multi-target synchronous interventions may be the path forward for discovering and developing potential neural repair strategies.
- Open Access
- 17 December 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1587246
Diet for the prevention and treatment of Parkinson’s disease
Parkinson’s disease (PD) is a common degenerative disease of the central nervous system with a variety of non-motor symptoms, in addition to the typical motor symptoms, which seriously affect the physical and mental health of patients, as well as their quality of life. All current treatment measures for PD only ameliorate and alleviate partial symptoms and signs in the early and middle stages. To date, no medicine or surgery can prevent PD progression. The search for preventive measures to treat and prevent PD is currently a research priority. Based on current related studies and investigations, diet interventions have now been found to play important roles in the treatment and prevention of PD. This article reviews recent research advances in diet in terms of polyphenols, fatty acids, vitamins, and dietary patterns for the prevention and treatment of PD.
- 17 December 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1587246
Open AccessDiet for the prevention and treatment of Parkinson’s disease
Parkinson’s disease (PD) is a common degenerative disease of the central nervous system with a variety of non-motor symptoms, in addition to the typical motor symptoms, which seriously affect the physical and mental health of patients, as well as their quality of life. All current treatment measures for PD only ameliorate and alleviate partial symptoms and signs in the early and middle stages. To date, no medicine or surgery can prevent PD progression. The search for preventive measures to treat and prevent PD is currently a research priority. Based on current related studies and investigations, diet interventions have now been found to play important roles in the treatment and prevention of PD. This article reviews recent research advances in diet in terms of polyphenols, fatty acids, vitamins, and dietary patterns for the prevention and treatment of PD.
- 20 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 106
The Potential Roles of HSPA2 in Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder traditionally identified by its characteristic motor symptoms, the presence of Lewy bodies, and the loss of neurons in the substantia nigra. At present, there is no cure for the disease. Our study aimed to uncover the new aspects of the pathogenesis underlying PD. Firstly, we identified that HSPA2 is potentially involved in the PD pathogenesis through a bioinformatic approach; HSPA2 was associated with the disease duration. For that, we analyzed the correlation of the clinical information of patients with the HSPA2 gene expression level. Then, the expression of HSPA2 was investigated in vivo using the midbrain from the MPTP-treated mouse models. The HSPA2 levels significantly increased in the midbrain tissue from the PD mouse models. The mechanistic studies about HSPA2 in the pathogenesis of PD were conducted in vitro in the HEK293T cell line, which observed the changes in α-synuclein expression by regulating the HSPA2 expression. In the HEK293T cell line, the overexpression of HSPA2 increased the α-synuclein aggregates formation, and the knockdown of HSPA2 reduced the α-synuclein aggregates accumulation. Therefore, this study hypothesized that HSPA2 might be a new regulator of α-synuclein associated with the PD pathology.
- 20 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 106
The Potential Roles of HSPA2 in Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder traditionally identified by its characteristic motor symptoms, the presence of Lewy bodies, and the loss of neurons in the substantia nigra. At present, there is no cure for the disease. Our study aimed to uncover the new aspects of the pathogenesis underlying PD. Firstly, we identified that HSPA2 is potentially involved in the PD pathogenesis through a bioinformatic approach; HSPA2 was associated with the disease duration. For that, we analyzed the correlation of the clinical information of patients with the HSPA2 gene expression level. Then, the expression of HSPA2 was investigated in vivo using the midbrain from the MPTP-treated mouse models. The HSPA2 levels significantly increased in the midbrain tissue from the PD mouse models. The mechanistic studies about HSPA2 in the pathogenesis of PD were conducted in vitro in the HEK293T cell line, which observed the changes in α-synuclein expression by regulating the HSPA2 expression. In the HEK293T cell line, the overexpression of HSPA2 increased the α-synuclein aggregates formation, and the knockdown of HSPA2 reduced the α-synuclein aggregates accumulation. Therefore, this study hypothesized that HSPA2 might be a new regulator of α-synuclein associated with the PD pathology.
- Open Access
- 17 July 2025
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 19, 1619775
Reduced nicotine dependence following traumatic brain injury in an elderly patient: a case report and literature review
Traumatic brain injury (TBI) can induce a range of neurological and behavioral changes, including potential effects on substance dependence. We present the case of an 87-year-old male with a longstanding history of heavy smoking (~60 pack-years) who demonstrated an abrupt cessation of nicotine craving following a severe TBI involving subdural hemorrhage, contusions, and subarachnoid hemorrhage. Clinical management included supportive therapy for intracranial pressure control and infection management. Nicotine dependence and craving were qualitatively assessed through repeated structured clinical interviews during hospitalization and outpatient follow-up. Remarkably, during the six-month follow-up, the patient remained abstinent without signs of withdrawal or nicotine craving and the use of pharmacological or behavioral interventions. This case highlights a rare but significant phenomenon suggesting that severe brain injury may disrupt mesolimbic dopaminergic circuits, including the ventral tegmental area (VTA) and nucleus accumbens (NAc), central to nicotine-related reward processing. We discuss potential neurobiological mechanisms post-injury, including dopaminergic dysfunction and health behavior adaptation. Further research is needed to elucidate the underlying pathways and clinical implications of TBI-associated changes in addictive behaviors.
- 17 July 2025
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 19, 1619775
Open AccessReduced nicotine dependence following traumatic brain injury in an elderly patient: a case report and literature review
Traumatic brain injury (TBI) can induce a range of neurological and behavioral changes, including potential effects on substance dependence. We present the case of an 87-year-old male with a longstanding history of heavy smoking (~60 pack-years) who demonstrated an abrupt cessation of nicotine craving following a severe TBI involving subdural hemorrhage, contusions, and subarachnoid hemorrhage. Clinical management included supportive therapy for intracranial pressure control and infection management. Nicotine dependence and craving were qualitatively assessed through repeated structured clinical interviews during hospitalization and outpatient follow-up. Remarkably, during the six-month follow-up, the patient remained abstinent without signs of withdrawal or nicotine craving and the use of pharmacological or behavioral interventions. This case highlights a rare but significant phenomenon suggesting that severe brain injury may disrupt mesolimbic dopaminergic circuits, including the ventral tegmental area (VTA) and nucleus accumbens (NAc), central to nicotine-related reward processing. We discuss potential neurobiological mechanisms post-injury, including dopaminergic dysfunction and health behavior adaptation. Further research is needed to elucidate the underlying pathways and clinical implications of TBI-associated changes in addictive behaviors.
- Open Access
- 30 May 2025
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (3) , 972-988
Potential common pathogenesis of several neurodegenerative diseases
With the gradual advancement of research methods and technologies, various biological processes have been identified as playing roles in the pathogenesis of neurodegenerative diseases. However, current descriptions of these biological processes do not fully explain the onset, progression, and development of these conditions. Therefore, exploration of the pathogenesis of neurodegenerative diseases remains a valuable area of research. This review summarizes the potential common pathogeneses of Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, frontotemporal lobar dementia, and Lewy body disease. Research findings have indicated that several common biological processes, including aging, genetic factors, progressive neuronal dysfunction, neuronal death and apoptosis, protein misfolding and aggregation, neuroinflammation, mitochondrial dysfunction, axonal transport defects, and gut microbiota dysbiosis, are involved in the pathogenesis of these six neurodegenerative diseases. Based on current information derived from diverse areas of research, these biological processes may form complex pathogenic networks that lead to distinctive types of neuronal death in neurodegenerative diseases. Furthermore, promoting the regeneration of damaged neurons may be achievable through the repair of affected neural cells if the underlying pathogenesis can be prevented or reversed. Hence, these potential common biological processes may represent only very small, limited elements within numerous intricate pathogenic networks associated with neurodegenerative diseases. In clinical treatment, interfering with any single biological process has proven insufficient to completely halt the progression of neurodegenerative diseases. Therefore, future research on the pathogenesis of neurodegenerative diseases should focus on uncovering the complex pathogenic networks, rather than isolating individual biological processes. Based on this, therapies that aim to block or reverse various targets involved in the potential pathogenic mechanisms of neurodegenerative diseases may be promising directions, as current treatment methods that focus on halting a single pathogenic factor have not achieved satisfactory efficacy.
- 30 May 2025
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (3) , 972-988
Open AccessPotential common pathogenesis of several neurodegenerative diseases
With the gradual advancement of research methods and technologies, various biological processes have been identified as playing roles in the pathogenesis of neurodegenerative diseases. However, current descriptions of these biological processes do not fully explain the onset, progression, and development of these conditions. Therefore, exploration of the pathogenesis of neurodegenerative diseases remains a valuable area of research. This review summarizes the potential common pathogeneses of Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, frontotemporal lobar dementia, and Lewy body disease. Research findings have indicated that several common biological processes, including aging, genetic factors, progressive neuronal dysfunction, neuronal death and apoptosis, protein misfolding and aggregation, neuroinflammation, mitochondrial dysfunction, axonal transport defects, and gut microbiota dysbiosis, are involved in the pathogenesis of these six neurodegenerative diseases. Based on current information derived from diverse areas of research, these biological processes may form complex pathogenic networks that lead to distinctive types of neuronal death in neurodegenerative diseases. Furthermore, promoting the regeneration of damaged neurons may be achievable through the repair of affected neural cells if the underlying pathogenesis can be prevented or reversed. Hence, these potential common biological processes may represent only very small, limited elements within numerous intricate pathogenic networks associated with neurodegenerative diseases. In clinical treatment, interfering with any single biological process has proven insufficient to completely halt the progression of neurodegenerative diseases. Therefore, future research on the pathogenesis of neurodegenerative diseases should focus on uncovering the complex pathogenic networks, rather than isolating individual biological processes. Based on this, therapies that aim to block or reverse various targets involved in the potential pathogenic mechanisms of neurodegenerative diseases may be promising directions, as current treatment methods that focus on halting a single pathogenic factor have not achieved satisfactory efficacy.